TNKASE (tenecteplase) / Roche, Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12345678910111213...1415»
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Review, Journal:  Stroke. (Pubmed Central) -  Jun 29, 2024   
    Regarding intracerebral haemorrhage, prompt delivery of bundled care consisting of immediate anticoagulation reversal, simultaneous blood pressure lowering, and prespecified stroke unit protocols can improve clinical outcomes. Guided by underlying stroke mechanisms, secondary prevention encompasses pharmacological, vascular, or endovascular interventions and lifestyle modifications.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Journal:  Angioedema After Use of Recombinant Tissue-Type Plasminogen Activators in Stroke. (Pubmed Central) -  Jun 28, 2024   
    Second, other-less frequently reported-adverse symptoms after r-tPA therapy and their proposed pathophysiological mechanisms leading to specific treatment are described. This manuscript describes the need for an update of the section "3.5 IV alteplase" from the American Heart Association/American Stroke Association guideline to treat this r-tPA-induced angioedema adequately and prevent potentially fatal outcomes.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Review, Journal:  Atrial Septal Aneurysm Leading to Ischemic Stroke: A Case Report and Literature Review. (Pubmed Central) -  Jun 25, 2024   
    Code stroke was called, and the patient was given tenecteplase (TNK), after which her right-side weakness and aphasia resolved...Patients with ASA and concomitant ASD are at high risk for recurrent ischemic stroke and should be kept under surveillance with continued medical therapy. We present a case of ischemic stroke caused by ASA and a review of the current literature and case reports documenting cases with similar presentations.
  • ||||||||||  AST-004 / Astrocyte Pharma, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Journal:  Lack of Interactions Between Alteplase/Tenecteplase and the Adenosine A1R/A3R Agonist AST-004. (Pubmed Central) -  Jun 24, 2024   
    In 2 different in vitro systems, AST-004 had no effect on the ability of alteplase or tenecteplase to generate plasmin, and AST-004 had no effect on the thrombolytic efficacy of alteplase to lyse blood clots in human blood. These studies indicate that there will be no interactions between AST-004 and tPAs such as alteplase or tenecteplase in patients with stroke undergoing thrombolytic therapy.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Journal:  Combining Early Ischemic Change and Collateral Extent for Functional Outcomes After Endovascular Therapy: An Analysis From AcT Trial. (Pubmed Central) -  Jun 24, 2024   
    The mCTA-ACE score was comparable to ICV to predict a modified Rankin scale score ?2 and return to prestroke level of function (C statistics 0.71 versus 0.69 and 0.68 versus 0.64, respectively). The mCTA-ACE score had a significant positive association with functional outcomes after endovascular therapy and had a similar predictive performance as ICV.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Journal:  Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy. (Pubmed Central) -  Jun 17, 2024   
    P3
    In this trial involving Chinese patients with ischemic stroke due to large-vessel occlusion, most of whom did not undergo endovascular thrombectomy, treatment with tenecteplase administered within 4.5 to 24 hours after stroke onset resulted in less disability and similar survival as compared with standard medical treatment, and the incidence of symptomatic intracranial hemorrhage appeared to be higher. (Funded by the National Natural Science Foundation of China and others; TRACE-III ClinicalTrials.gov number, NCT05141305.).
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Journal:  Intravenous tenecteplase for acute ischemic stroke between 4.5 and 6?h of onset (EXIT-BT2): Rationale and Design. (Pubmed Central) -  Jun 11, 2024   
    The primary efficacy endpoint is excellent functional outcome, defined as a modified Rankin Scale score 0-1 at 90?days after randomization, while the primary safety endpoint is symptomatic intracerebral hemorrhage, defined as National Institutes of Health Stroke Scale score increase ?4 caused by intracranial hemorrhage within 24 (-6/+12)?h after randomization. The results of EXIT-BT2 may determine whether intravenous TNK has a favorable risk/benefit profile in AIS between 4.5 and 6?h of onset.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Journal:  Door to Needle Time Trends after Transition to Tenecteplase: A Multicenter Texas Stroke Registry. (Pubmed Central) -  May 26, 2024   
    When stratified by hospital, the three subgroups demonstrated variable DTN time trends which highlight the potential for either fatigue or unpreparedness when switching to TNK. Because our study included a multi-ethnic cohort from multiple large Texas cities, the stable DTN times after transition to TNK is likely applicable to other healthcare systems.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Journal:  Tenecteplase for Stroke at 4.5 to 24 Hours. Reply. (Pubmed Central) -  May 8, 2024   
    These findings allow to identify patients at high risk of ICH. No abstract available
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Review, Journal:  Comprehensive Review of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. (Pubmed Central) -  May 7, 2024   
    Clinical trials have demonstrated that tenecteplase is not inferior to alteplase and may even be superior in cases of acute ischemic stroke with large vessel occlusion. Current evidence supports the time and cost benefits of tenecteplase, suggesting that it could potentially replace alteplase as the main option for thrombolytic therapy, especially in patients with large vessel occlusion.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
    Retrospective data, Review, Journal:  Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Systematic Review and Meta-analysis. (Pubmed Central) -  May 2, 2024   
    The patients in TNK group showed early neurological improvement but were simultaneously at higher risk of ICH. The TNK can be an alternative to alteplase if the benefits outweigh the risks.
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Journal:  Angioedema Following Tenecteplase for Acute Ischemic Stroke. (Pubmed Central) -  Apr 25, 2024   
    A Randomized Controlled Trial of tenecteplase Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion, Registration number: NCT02398656; URL: https://clinicaltrials.gov/study/NCT02398656. No abstract available
  • ||||||||||  NoNO-42 / NoNO, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    New P3 trial:  ACT-GLOBAL Adaptive Platform Trial for Stroke (clinicaltrials.gov) -  Apr 8, 2024   
    P3,  N=20000, Not yet recruiting,